Rifapentine
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | PRIFTIN | — | 2000-10-20 – 2014-11-25 | fda.gov ↗ |
| Approved | US (FDA) | PRIFTIN | — | 1998-06-22 | fda.gov ↗ |
Trials 63 · started per year
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05630872 Background | Feb 2024 → May 2025 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02980016 Comparator | Nov 2016 → Oct 2019 | HIV infectious disease, tuberculosis | The Aurum Institute NPC | Completed | No outcome recorded |
| Phase 3 | NCT00057122 Comparator | Sep 2002 → Nov 2008 | HIV infectious disease, tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06874725 Comparator | Apr 2018 → Apr 2024 overdue | latent tuberculosis infection | Taichung Veterans General Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 69 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rifapentine | “A recent multi-centered, multi-national randomized control non inferiority trial with approximately 4,000 patients per arm demonstrated that Rifapentine and INH (3HP) given...” NCT02689089 ↗67“Once-weekly isoniazid and rifapentine for 3 months is a treatment option in persons with human immunodeficiency virus and latent tuberculosis infection.” PMID 29415190 ↗ Jul 2018 “8 weeks of daily isoniazid, rifapentine, moxifloxacin and pyrazinamide, followed by 9 weeks of daily isoniazid, rifapentine and moxifloxacin.” NCT07608172 ↗ “Oral chemoprophylaxis will be standard of care - either 6 months of Isoniazid or 3 months of weekly Isoniazid and Rifapentine” NCT05330884 ↗ “weekly oral Rifapentine 15 mg/kg (up to 900mg) plus Isoniazid 15 mg/kg (up to 900mg) for 12 doses” NCT02430259 ↗ “daily rifapentine (R) and moxifloxacin (M) plus isoniazid (H) and pyrazinamide (P)” NCT05630872 ↗ “high-dose rifapentine (P), isoniazid (H), pyrazinamide (Z), and moxifloxacin (M)” NCT06153069 ↗ “Rifapentine (RPT) 900 mg once-weekly x 12 doses (3 months)” NCT00023452 ↗ “once-weekly rifapentine (RPT) and isoniazid (INH) (3HP)” NCT05122767 ↗ “Rifapentine” NCT02099240 ↗ |
| Known as | ANTIBIOTIC DL-473IT | ChEMBL registry synonym — accepted as the source's own label CHEMBL1660 ↗ |
| Known as | DL-473 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1660 ↗ |
| Known as | KTC-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1660 ↗ |
| Known as | M000473 | “rifapentine (M000473)” NCT01690403 ↗ |
| Known as | MDL 473 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1660 ↗ |
| Known as | Prifitin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1660 ↗ |
| Known as | Priftin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1660 ↗ |
| Known as | Priftin - Rifapentine | “Priftin - Rifapentine” NCT00809718 ↗1“Priftin (rifapentine)” NCT02980016 ↗ |
| Known as | R-77-3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1660 ↗ |
| Known as | Rifapentin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1660 ↗ |
| Known as | Rifapentina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1660 ↗ |
| Known as | Rifapentine RPT | “Rifapentine RPT” NCT03900858 ↗ |
| Known as | RPT | “The investigators hypothesize that short-course (4-week) daily isoniazid/rifapentine (INH/RPT) (1HP) is not inferior to standard -course (12 weeks) INH/RPT weekly regimen (3HP)...” NCT03785106 ↗11“600 mg of Rifapentine (RPT) given once daily (o.d., omni die) for 6 weeks (6wP).” NCT03474029 ↗ “steady-state dolutegravir (DTG) and rifapentine (RPT) concentrations” NCT06281834 ↗ “escalating doses of rifapentine (RPT) administered daily by oral” NCT01162486 ↗ “once-weekly rifapentine (RPT) and isoniazid (INH) (3HP)” NCT05122767 ↗ “rifapentine (RPT, 900 mg)” NCT04600167 ↗ “Drug: Rifapentine (RPT)” NCT06917495 ↗ “Rifapentine (RPT)” NCT04272242 ↗ “Rifapentine (RPT)” NCT01574638 ↗ “Rifapentine (RPT)” NCT02651259 ↗ “Rifapentine (RPT)” NCT03886701 ↗ “Rifapentine (RPT)” NCT01404312 ↗ |
| Modality | Small molecule | — CHEMBL1660 ↗ |
| Route | Oral | “Rifapentine plus Isoniazid taken orally, weekly, by direct observation for 12 weeks” NCT00164450 ↗ |